154 related articles for article (PubMed ID: 37607790)
21. Non-alcoholic steatohepatitis is independently associated with a history of gestational diabetes mellitus.
Boustany A; Onwuzo S; Zeid HKA; Almomani A; Kumar P; Hitawala A; Asaad I
J Gastroenterol Hepatol; 2023 Jun; 38(6):984-988. PubMed ID: 36869600
[TBL] [Abstract][Full Text] [Related]
22. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
23. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
[TBL] [Abstract][Full Text] [Related]
24. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
25. Is cryptogenic cirrhosis different from NASH cirrhosis?
Thuluvath PJ; Kantsevoy S; Thuluvath AJ; Savva Y
J Hepatol; 2018 Mar; 68(3):519-525. PubMed ID: 29162389
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
27. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
Fialoke S; Malarstig A; Miller MR; Dumitriu A
AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.
Shah AS; Khan S; Rahim H; Chishti KA; Khan AG
Pak J Pharm Sci; 2018 Jan; 31(1):193-198. PubMed ID: 29348103
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
[TBL] [Abstract][Full Text] [Related]
30. [Association between serum sex hormone-binding globulin and non-alcoholic steatohepatitis].
Zhao XY; Gu TW; Fang D; Sun HX; Bi Y
Zhonghua Nei Ke Za Zhi; 2022 Nov; 61(11):1239-1246. PubMed ID: 36323566
[No Abstract] [Full Text] [Related]
31. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.
Stepanova M; Henry L; Garg R; Kalwaney S; Saab S; Younossi Z
BMC Gastroenterol; 2015 Dec; 15():175. PubMed ID: 26666336
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
33. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Tasneem AA; Luck NH; Majid Z
Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
35. Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index.
Funada K; Kusano Y; Gyotoku Y; Shirahashi R; Suda T; Tamano M
World J Gastroenterol; 2023 Jun; 29(23):3703-3714. PubMed ID: 37398885
[TBL] [Abstract][Full Text] [Related]
36. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.
Danford CJ; Iriana S; Shen C; Curry MP; Lai M
Liver Int; 2019 Jun; 39(6):1165-1173. PubMed ID: 30809932
[TBL] [Abstract][Full Text] [Related]
37. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
Nah EH; Cho S; Park H; Noh D; Kwon E; Cho HI
PLoS One; 2021; 16(11):e0260477. PubMed ID: 34818372
[TBL] [Abstract][Full Text] [Related]
38. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
39. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
Michel M; Kalliga E; Labenz C; Straub BK; Wörns MA; Galle PR; Schattenberg JM
Z Gastroenterol; 2020 Jan; 58(1):57-62. PubMed ID: 31931541
[TBL] [Abstract][Full Text] [Related]
40. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
